Prana Biotechnology Receives FDA Approval to Commence Clinical Trial for Huntington's Disease Drug; Shares Gain Nearly 9%

By
A A A

Prana Biotechnology Limited ( PRAN ) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to start recruiting patients for the company's first clinical trial using the experimental drug PBT2 in patients with Huntington's Disease ( HD ).

The trial will be randomised, double-blind, placebo-controlled and will enroll 100 patients with early to mid-stage Huntington's Disease. The primary objective is to determine the safety and tolerability of two dose levels of PBT2 when administered orally once daily over 26 weeks in patients with HD.

Shares are up 8.90% to $1.59, but off a day high $1.75.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


This article appears in: Investing , Commodities

Referenced Stocks: HD , PRAN

MT Newswires

MT Newswires

More from MT Newswires:

Related Videos

Stocks

Referenced

Most Active by Volume

55,414,702
  • $15.38 ▼ 0.39%
38,503,210
  • $66.34 ▲ 2.26%
36,466,704
  • $8.36 ▼ 9.52%
35,253,294
  • $26.55 ▲ 1.34%
32,752,347
  • $6.55 ▲ 1.87%
31,778,001
  • $95.22 ▲ 0.19%
28,396,556
  • $51.49 ▼ 0.62%
23,800,987
  • $42.09 ▲ 0.97%
As of 7/11/2014, 04:03 PM